Lantern Pharma Inc. 2024 Q1 Form 10-Q Summary
Business Context and Reporting Period
Lantern Pharma Inc. is a clinical-stage biotechnology company using its RADR® artificial intelligence, machine learning, genomic and biomarker platform to develop targeted oncology therapies. The company is advancing LP-300 in Phase 2, LP-184/STAR-001 and LP-284 in Phase 1 trials, and an antibody-drug conjugate program in preclinical development. The quarter ended March 31, 2024; the filing was dated May 9, 2024.
The company has not generated revenue other than a prior research grant and operates as a single segment. Its interim financial statements are unaudited and prepared under U.S. GAAP.
Financial Metrics
| Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $1.481 million | $1.733 million |
| Research and development expense | $4.251 million | $2.553 million |
| Total operating expenses | $5.732 million | $4.286 million |
| Loss from operations | $(5.732) million | $(4.286) million |
| Interest income | $0.201 million | $0.134 million |
| Other income, net | $0.090 million | $0.285 million |
| Net loss | $(5.441) million | $(3.868) million |
| Basic and diluted loss per share | $(0.51) | $(0.36) |
| Cash used in operating activities | $(3.069) million | $(3.757) million |
Because the company reported no revenue, operating and net profit margins are not meaningful. As of March 31, 2024, cash and cash equivalents were $18.358 million, marketable securities were $20.000 million, and working capital was approximately $35.517 million. Total assets were $39.734 million and total liabilities were $3.969 million. The company had no long-term debt; liabilities consisted primarily of accounts payable, accrued expenses and operating leases.
Cash, cash equivalents and marketable securities totaled approximately $38.4 million. Marketable securities included government and agency securities, corporate bonds and mutual funds. Substantially all cash held at financial institutions exceeded FDIC insurance limits.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $1.698 million, or 67%, primarily due to higher research study, payroll and consulting costs. LP-184 expenses increased to $2.233 million from $1.130 million, and LP-300 expenses increased to $1.052 million from $0.634 million.
- General and administrative expense decreased $0.252 million, or 15%, primarily due to lower payroll, insurance, professional fees, and office and administrative costs.
- Net loss increased $1.573 million, or approximately 41%, to $5.441 million, despite higher interest income and lower general and administrative expense.
- Operating cash use decreased $0.689 million, or approximately 18%, principally because accounts payable and accrued expenses increased during the quarter.
- Investing cash use decreased to $0.556 million from $0.961 million, reflecting lower net purchases of marketable securities.
- Cash flow from financing activities was $0.055 million, resulting from warrant exercises; there was no financing cash flow in the prior-year quarter.
- The company issued 37,613 common shares in connection with warrant exercises, including 17,481 shares for aggregate proceeds of $54,716 and 20,132 shares through cashless exercises.
- R&D expenses for license, strategic alliance and research agreements increased to approximately $2.102 million from $1.248 million. Amounts accrued and payable under these agreements increased to approximately $2.163 million from $1.563 million.
Guidance, Outlook, Risks and Unusual Items
- Management expects R&D expenses and operating losses to increase as clinical trials for LP-300, LP-184 and LP-284 progress and as other programs advance.
- The company believes its cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements for at least 12 months from the filing date. However, management expects to require substantial additional funding to complete clinical trials.
- Potential funding sources include periodic equity offerings, grants and possible commercial credit facilities. Equity financing could dilute existing shareholders; debt financing could create fixed payment obligations and restrictive covenants.
- If additional capital is unavailable, the company may need to delay, reduce or discontinue development programs, seek collaborations earlier than planned, or license rights on less favorable terms.
- Clinical, regulatory and commercial risks include uncertainty regarding enrollment, trial timing, efficacy, manufacturing, competition, regulatory approval and market acceptance. No drug candidate has received regulatory or marketing approval.
- The company terminated a Fortrea start-up work order related to the LP-284 Phase 1 trial during the first quarter. In May 2024, after quarter-end, it amended the Fortrea work order for the LP-184 Phase 1 trial to add services.
- The collaboration agreement with Actuate Therapeutics expired or was scheduled to expire on March 31, 2024, and the company was discussing an extension. No revenue had been recognized under that agreement through March 31, 2024.
- Marketable securities had approximately $0.506 million of aggregate unrealized losses at March 31, 2024. Management did not consider these losses to represent credit losses, but investment values remain exposed to interest-rate and market fluctuations.
- The company reported foreign currency losses of approximately $0.099 million during the quarter and does not hedge foreign currency exposure.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Clinical progress, enrollment and interim or final results for the LP-300 Harmonic trial and the LP-184 and LP-284 Phase 1 trials.
- Whether the company secures additional financing, grant funding or commercial credit before its available liquidity is exhausted.
- The pace and composition of R&D spending, particularly the increasing costs associated with LP-184 and external research agreements.
- The terms and potential dilution associated with future equity financing, warrant exercises and outstanding options and warrants.
- The status of the Actuate collaboration and the financial or development impact of the Fortrea work-order changes.
- The valuation and liquidity risks associated with the company’s marketable securities, including losses on mutual funds and other investments.
- Whether any pipeline candidate ultimately demonstrates sufficient safety and efficacy to obtain regulatory approval and commercial adoption.